Vital signs, comprising SBP, diastolic BP (DBP), and pulse rate, were measured at 13 timepoints (from week 0 to week 68)
Evidence Limitations and Unanswered Questions The main evidence limitations for GHK-Cu are uneven human data, formulation differences, limited injectable safety information, small topical skin studies, indirect hair evidence, and uncertain long-term outcomes [2], [6], [7], [8]
This material is not a medicine, food, dietary supplement, cosmetic, diagnostic product, or household product
Astaxanthin influence on health outcomes of adults at risk of metabolic syndrome: A systematic review and meta-analysis
Synthetic peptide hydrogels as 3D scaffolds for tissue engineering
ESI-MS study of the mechanism of glycyl-l-histidyl-l-lysine-Cu(II) complex transport